New voice valve may cut frequent replacements for throat cancer survivors

NCT ID NCT07369050

First seen Jan 27, 2026 · Last updated Jun 15, 2026 · Updated 25 times

Summary

This study looks at whether using the Provox ActiValve voice prosthesis as a first-choice device can lower the number of replacements needed each year in people who have had their voice box removed (total laryngectomy) and a tracheoesophageal puncture (TEP). About 48 adults who are at least 6 months past cancer treatment and currently use or are ready for an indwelling voice prosthesis will be randomly assigned to get either the ActiValve or a standard device. The main goal is to see if the ActiValve leads to fewer device changes and fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77090, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.